20 November 2014
EMA/785545/2014
Procedure Management and Business Support Division

Committee for medicinal products for human use (CHMP)

Minutes of the meeting held on 17-20 November 2014

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Disclaimers

Some of the information contained in this agenda is considered commercially confidential and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the CHMP are on-going and therefore are considered confidential. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. For orphan medicinal products the applicant details are published as this information is already publicly available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Agenda (EMA/CHMP/659045/2014 rev.4) and Annex to CHMP agenda of the CHMP plenary session to be held 17-20 November 2014	The agenda and annex were adopted with amendments.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Timeschedule (EMA/CHMP/686385/2014 rev.3) of the CHMP plenary session to be held 17-20 November 2014	The timeschedule was adopted.
Minutes (EMA/CHMP/679758/2014 rev.0) of the CHMP plenary session held 20-23 October 2014	The Minutes of the CHMP plenary session held 20-23 October 2014 were adopted.
TOD / Minutes (EMA/CHMP/695849/2014) of the ORGAM meeting held on 10 November 2014	The Minutes of the November 2014 CHMP ORGAM meeting held on 10 November 2014, together with all decisions taken at that meeting, were adopted.

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 17-20 November 2014	*See November 2014 Minutes (to be published post December 2014 CHMP meeting)* The pre-meeting list was noted.
Draft Agenda of CHMP meeting to be held on 15-18 December 2014.	The draft agenda was noted.

Table of contents

1. Oral explanations

1.1. Pre-authorisation procedure oral explanations

Vantobra (EMEA/H/C/002633)
(Tobramycin), Applicant: PARI Pharma GmbH, Hybrid application (Article 10(3) of Directive No 2001/83/EC)
An Oral explanation was held on Tuesday 18 November 2014 at 14.00.
See also 2.5 Products in the Decision Making Phase

(EMEA/H/C/002396), (safinamide), (treatment of Parkinson's disease (PD)
List of Outstanding Issues adopted on 25.09.2014. List of Questions adopted on 25.04.2014.
An Oral explanation was held on Wednesday 19 November at 9.00.
The Oral explanation focused on the efficacy and safety in early stage patients.

1.2. Re-examination procedure oral explanation

No items

1.3. Post-authorisation procedure oral explanation

ellaOne (EMEA/H/C/001027/II/0021), (ulipristal acetate), MAH: Laboratoire HRA Pharma, SA, Rapporteur: Pieter de Graeff, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst
"Change in the classification for supply of ellaOne from "medicinal product subject to medical prescription" to "medicinal product not subject to medical prescription". An update of the Product information in line with a non-prescription setting was performed. Updates of SmPC sections 4.2, 4.4 and 5.1 were also performed based on Repeated use study (HRA2914-554) and on the STEella study in postmenarcheal girls and adult women (HRA 2914-515). Additionally, the contraindication "pregnancy" was removed based on available non-clinical and clinical data. Updates to Annex II, labelling and package leaflet have been made accordingly. Furthermore, changes were made to the PI to bring it in line with the current Agency/QRD template. In addition, editorial changes have been made in the Product Information."
Request for Supplementary Information adopted on 23.01.2014, 21.11.2013, 25.04.2013.
Request for 1 year of data exclusivity for a change in classification (Article 74(a) of Directive 2001/83/EC)
An Oral explanation was held on Tuesday 18 November 2014 at 11.00.
See also 11. Post-authorisation Issues

1.4. Referral procedure oral explanation

No items

2. New full applications

2.1. New full applications; Opinions

Cerdelga (EMEA/H/C/003724), Orphan, (eliglustat), Applicant: Genzyme Europe BV, (treatment of Gaucher disease type 1)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 25.09.2014., 24.07.2014.
List of Questions adopted on 20.02.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that eliglustat is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The Committee noted the letter of recommendation dated 19.11.2014.
The summary of opinion was circulated for information.

Cosentyx (EMEA/H/C/003729), (secukinumab), Applicant: Novartis Europharm Ltd, (treatment of plaque psoriasis)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 25.09.2014.
List of Questions adopted on 20.03.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive Opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that secukinumab is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The Committee noted the letter of recommendation dated 18.11.2014.
The summary of opinion was circulated for information.
The Committee adopted the BWP Report.

Exviera (EMEA/H/C/003837), (dasabuvir), Applicant: AbbVie Ltd., (treatment of chronic hepatitis C)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Questions adopted on 25.09.2014.
Opinion at D150 (accelerated assessment).
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive Opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that dasabuvir is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

Ofev (EMEA/H/C/003821), Orphan, (nintedanib), Applicant: Boehringer Ingelheim International GmbH, (treatment of Idiopathic Pulmonary Fibrosis (IPF))
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Questions adopted on 25.09.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive Opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that nintedanib is a new active substance at the time of application, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

Otezla (EMEA/H/C/003746), (apremilast), Applicant: Celgene Europe Limited (treatment of psoriatic arthritis, psoriasis) New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 25.09.2014. List of Questions adopted on 25.04.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus recommending the granting of a marketing authorisation together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that apremilast is a new active substance, as claimed by the applicant.
The legal status was agreed as medicinal product subject to medical prescription.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The Committee noted the letter of recommendation dated 19.11.2014.
The summary of opinion was circulated for information.
The Committee adopted the SWP response.

Senshio (EMEA/H/C/002780), (ospemifene), Applicant: Shionogi Limited, (treatment of vulvar and vaginal atrophy (VVA))
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 24.07.2014, 20.03.2014.
List of Questions adopted on 25.07.2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive Opinion recommending the granting of a marketing authorisation by majority (23 out of 29) together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that Ospemifene is a new active substance, as claimed by the Shionogi Limited.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The divergent position (Pierre Demolis, Harald Enzmann, Concepcion Prieto-Yerro, Dimitrios Kouvelas, Sol Ruiz, Jan Mueller-Berghaus) was appended to the opinion.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

Sevelamer carbonate Zentiva (EMEA/H/C/003971), (sevelamer), Applicant: Genzyme Europe BV, (control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis)
Informed consent application (Article 10c of Directive No 2001/83/EC)
List of Questions adopted on 23.10.2014.
The Committee adopted a positive Opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

Rasagiline Ratiopharm (EMEA/H/C/003957), (rasagiline), Applicant: Teva B.V., (treatment of Parkinson's disease)
Informed consent application (Article 10c of Directive No 2001/83/EC) The Committee adopted a positive Opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

Viekirax (EMEA/H/C/003839), (ombitasvir / paritaprevir / ritonavir), Applicant: AbbVie Ltd., (treatment of chronic hepatitis C)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Questions adopted on 25.09.2014. Opinion at D150 (accelerated assessment).
The Committee adopted a positive Opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that International non-proprietary name ombitasvir and paritaprevir are new active substances, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

Zontivity (EMEA/H/C/002814), (vorapaxar), Applicant: Merck Sharp & Dohme Limited, (indicated for the reduction of atherothrombotic events)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 25.09.2014. List of Questions adopted on 25.04.2014. The
The CHMP noted the report from the SAG CVS. The experts gave recommendations regarding co-administration of Zontivity with other anticoagulants in light with a potential increased risk of bleeding. Furthermore the SAG recommended a limited treatment duration based on the available clinical data. The experts also advised on a careful assessment in specific patient subgroups with a potential higher bleeding risk.
The Committee discussed the available data and made amendments to the SmPC wording. The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive Opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that Vorapaxar is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

2.2. New full applications; Day 180 List of outstanding issues

(EMEA/H/C/004006), (clopidogrel), (prevention of myocardial infarction and acute coronary syndrome
Myocardial infarction, ischaemic stroke, peripheral arterial disease, acute coronary syndrome, prevention of atherothrombotic and thromboembolic events in atrial fibrillation
Myocardial infarction, ischaemic stroke, peripheral arterial disease, acute coronary syndrome, prevention of atherothrombotic and thromboembolic events in atrial fibrillation
Myocardial infarction, ischaemic stroke, peripheral arterial disease, acute coronary syndrome, prevention of atherothrombotic and thromboembolic events in atrial fibrillation.)
Request for Supplementary Information adopted on 25.09.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002830), Orphan, (mifepristone), Applicant: FGK Representative Service GmbH, (treatment of Cushing's syndrome)
List of Questions adopted on 20.03.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002788), Orphan, (tolvaptan), Applicant: Otsuka Pharmaceutical Europe Ltd, (treatment of kidney disease (ADPKD)
List of Questions adopted on 25.04.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a List of Outstanding Issues with a specific timetable.
The CHMP discussed the need for a SAG and agreed that this was not required at this stage.

(EMEA/H/C/003823), (lamivudine / raltegravir), (treatment of human immunodeficiency virus (HIV-1)
List of Questions adopted on 24.07.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues,
The CHMP adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002629), (edoxaban), (prevention of stroke; embolism and treatment of venous thromboembolism)
List of Questions adopted on 26.06.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/003785), (oritavancin), (treatment of complicated skin and soft tissue infections (cSSTI))
List of Questions adopted on 26.06.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues .
The CHMP adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002789), Orphan, (levofloxacin), Applicant: Aptalis Pharma SAS, (indicated for chronic pulmonary infections)
List of Outstanding Issues adopted on 25.09.2014. List of Questions adopted on 25.04.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a 2nd List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002807), (human fibrinogen / human thrombin), (Supportive treatment where standard surgical techniques are insufficient for improvement of hemostasis)
List of Questions adopted on 20.03.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues,
The CHMP adopted a List of Outstanding Issues with a specific timetable.
The Committee adopted the BWP Report.

(EMEA/H/C/002739), ((substance to be reviewed) human alpha1-proteinase inhibitor), (treatment of lung tissue)
List of Questions adopted on 25.04.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a List of Outstanding Issues with a specific timetable.
The CHMP adopted a list of questions to the ad-hoc expert group meeting.
The Committee adopted the BWP Report.

(EMEA/H/C/002846), (tedizolid phosphate), (treatment of tissue infections (cSSTI))
List of Questions adopted on 26.06.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/003737), (voriconazole), (treatment of fungal infections)
List of Questions adopted on 24.07.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP adopted a List of Outstanding Issues with a specific timetable.

2.3. New full applications; Day 120 List of Questions –

(EMEA/H/C/003899), (aripiprazole), (treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions

(EMEA/H/C/003926), (aripiprazole), (treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions

(EMEA/H/C/003803), (aripiprazole), (treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions

(EMEA/H/C/004008), (aripiprazole), (treatment of schizophrenia and treatment and prevention of manic episodes in bipolar I disorder)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions

(EMEA/H/C/003904), (atazanavir / cobicistat), (treatment of HIV-1 infected, combination with other antiretroviral medicinal products.)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions

(EMEA/H/W/002300), (p. falciparum circumsporozoite protein fused with hepatitis b surface antigen (rts), and combined with hepatitis b surface antigen (s) in the form of non-infectious virus-like particles (vlps) produced in yeast cells (saccharomyces cerevisiae) by recombinant dna technology), (indicated for active immunisation against malaria)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions
The CHMP agreed to consult a SAG (with additional experts).
The Committee adopted the BWP Report.

(EMEA/H/C/002792), Orphan, (susoctocog alfa), Applicant: Baxter AG, (treatment of acquired haemophilia A)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions
The Committee adopted the BWP Report.

(EMEA/H/C/003789), (pegaspargase), (indicated as combination therapy in acute lymphoblastic leukaemia (ALL))
The Committee discussed the issues identified in this application,
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions
The Committee adopted the BWP Report and the BWP Similarity report.
The CHMP adopted the CHMP Assessment Report on similarity

(EMEA/H/C/003910), (pegfilgrastim), (treatment of neutropenia)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions

(EMEA/H/C/003794), Orphan, (asfotase alfa), Applicant: Alexion Europe SAS, (treatment of paediatric-onset hypophosphatasia)
The Committee discussed the issues identified in this application,
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions
The Committee adopted the BWP Report.

(EMEA/H/C/003770), (empagliflozin / metformin hydrochloride), (treatment of type II diabetes)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions

(EMEA/H/C/002784), (sufentanil), (indicated for the management pain)
The Committee discussed the issues identified in this application
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions

2.4. Update on on-going new full applications for Centralised procedure

(EMEA/H/C/003725), Orphan, (panobinostat), Applicant: NOVARTIS PHARMACEUTICALS UK LIMITED, (treatment of multiple myeloma)
The Committee agreed to the request by the applicant for an extension of the clock stop to respond to the Day 120 List of Questions adopted in September.

(EMEA/H/C/003773), (cangrelor), (inhibitor indicated for the reduction of thrombotic cardiovascular events)
List of Outstanding Issues adopted on 25.09.2014.
List of Questions adopted on 25.04.2014.
The CHMP noted the list of experts which had been adopted via written procedure.
The CHMP adopted an updated list of questions to the expert group .

(EMEA/H/C/003702), (phenylephrine hydrochloride / ketorolac trometamol), (maintenance of mydriasis, prevention of miosis and reduction of ocular pain replacement (ILR).)
List of Outstanding Issues adopted on 22.05.2014.
List of Questions adopted on 23.01.2014.
The Committee adopted the list of experts for the Ad hoc expert group meeting.

(EMEA/H/C/002066), (ciclosporin), (treatment of severe keratitis in adults with dry eye disease)
List of Questions adopted on 25.04.2014.
The Committee adopted the list of experts for the Ad hoc expert group meeting.

(EMEA/H/C/003769), Orphan, (mercaptamine hydrochloride), Applicant: Orphan Europe S.A.R.L., (treatment of cystinosis)
The CHMP adopted a revised timetable on similarity assessment.

2.5. Products in the Decision Making Phase

Vantobra (EMEA/H/C/002633)
(Tobramycin), Applicant: PARI Pharma GmbH, An Oral explanation was held on Tuesday 18 November 2014 at 14.00.
See also 1.1 Pre-authorisation oral explanations.
The CHMP adopted a specific timetable.

3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

3.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinions

No items

3.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 List of outstanding issues

Ibandronic acid Accord (EMEA/H/C/002638/X/0006), (ibandronic acid), MAH: Accord Healthcare Ltd, Rapporteur: Alar Irs, "To add a new strength/potency and a new pharmaceutical form 3 mg solution for injection."
List of Questions adopted on 26.06.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues, concerning an update of the quality specifications for benzene and amendment of the RMP and SmPC wording.
The CHMP adopted a List of Outstanding Issues with a specific timetable.

3.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of Questions

Jetrea (EMEA/H/C/002381/X/0013), (ocriplasmin), MAH: ThromboGenics NV, Rapporteur: Greg Markey, PRAC Rapporteur: Julie Williams, "to introduce a ready-to-use (RTU) formulation with adjusted fill volume for Jetrea 0.375 mg/0.3 mL"
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

3.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

Orfadin (EMEA/H/C/000555/X/0041), Orphan, (nitisinone), MAH: Swedish Orphan Biovitrum International AB, Rapporteur: Luca Pani, PRAC Rapporteur: Carmela Macchiarulo "To add an oral suspension 4 mg/ml as additional pharmaceutical form"
List of Outstanding Issues adopted on 23.10.2014. List of Questions adopted on 19.12.2013.
The Committee agreed to the request and adopted a revised timetable.

4. Type II variations - Extension of indication procedures according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Type II variation; Extension of indication- Opinions or Requests for supplementary information

Adenuric (EMEA/H/C/000777/II/0037), (febuxostat), MAH: Menarini International Operations Luxembourg S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC for the 120 mg strength further to the introduction of a new indication for prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS). The Package Leaflet is updated accordingly."
The Committee discussed the issues identified in this application, which were related to the extension of indication. 1-year market protection was considered appropriate in the new therapeutic indication, because of the significant clinical benefit in comparison with existing therapies.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Esmya (EMEA/H/C/002041/II/0028), (ulipristal), MAH: Gedeon Richter Plc., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.1 of the SmPC with subsequent updates to sections 4.2, 4.4, 4.8 and 5.1 in order to extend the current indication to long term (repeated intermittent) treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The Package Leaflet is updated accordingly."
The Committee discussed the issues identified in this application, related to extension of indication and endometrial safety.
The Committee adopted a Request for Supplementary Information with a specific timetable.

InductOs (EMEA/H/C/000408/II/0071), (dibotermin alfa), MAH: Medtronic BioPharma B.V., Rapporteur: Pieter de Graeff, Co-Rapporteur: Janne Komi, PRAC Rapporteur: Menno van der Elst, "Extension of the indication to broaden (anatomically) the use of InductOs in lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non-operative treatment for this condition in the treatment of adults. Consequently, sections 4.1, 4.2, 4.8, 4.9 and 5.1 of the SmPC have been updated. Further, SmPC section 4.4 has been updated with warnings related to type of surgery, device and spinal level, and sections 4.4, 4.5, 4.6, 5.1 and 5.3 of the SmPC based on supportive non-clinical and clinical data relating to immunogenicity, tumorigenicity or fusion success. The Package Leaflet was updated accordingly. Furthermore, the standard term has been updated from "kit for implant" to "powder, solvent and matrix", and the expression of the strength changed from "12mg" to "1.5 mg/ml" throughout the SmPC, labelling and Package leaflet. In addition, the MAH took the opportunity to implement the latest QRD template (version 9.0) and to make editorial changes throughout the annexes. A revised RMP version 2 was agreed as part of the procedure."
Request for Supplementary Information adopted on 24.07.2014.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive Opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.

Invega (EMEA/H/C/000746/II/0043), (paliperidone), MAH: Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Qun-Ying Yue, "Update of sections 4.1 of the SmPC in order to extend the Invega indication to include depressive symptom domain of schizoaffective disorder. Additionally section 5.1 has been updated to reflect the data from the study SCA-3004 on paliperidone palmitate effects in the maintenance of symptom control. Minor editorial changes have been introduced throughout the PI. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."
The Committee discussed the issues identified in this application.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Relistor (EMEA/H/C/000870/II/0030), (methylnaltrexone bromide), MAH: TMC Pharma Services Ltd, Rapporteur: Harald Enzmann, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Valerie Strassmann, "The MAH applied for an extension of the indication for the treatment of opioid induced constipation in adult non cancer pain patients. Consequently, the MAH proposed the update of sections 4.1, 4.2, 4.4 and 5.1 of the SmPC. The Package Leaflet was proposed to be updated in accordance."
Request for Supplementary Information adopted on 26.06.2014.
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)
The Committee discussed the issues identified in this application, which were related to submitted studies and extension of data protection period, furthermore the suggestion to grant a second-line indication only was discussed.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Rienso (EMEA/H/C/002215/II/0008), (ferumoxytol), MAH: Takeda Pharma A/S, Rapporteur: Harald Enzmann, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Martin Huber, "Extension of indication: all cause iron deficiency anaemia when oral therapy is ineffective or inappropriate or where there is a need for rapid iron repletion
As a consequence, sections 4.1, 4.2 , 4.4, 4.8 and 5.1 of the SmPC were proposed to be updated. The Package Leaflet was proposed to be updated accordingly. The MAH took the opportunity to propose minor editorial changes to the SmPC and to propose the update of the Product Information in line with the latest version of the QRD template (9.0)"
Request for Supplementary Information adopted on 26.06.2014, 25.04.2014, 24.10.2013.
The Committee discussed the issues identified in this application, which were related to clinical safety of the product in relation to granting of the extension of indication for all cause IDA.
The Committee adopted a 4th Request for Supplementary Information with a specific timetable.

Soliris (EMEA/H/C/000791/II/0066), Orphan, (eculizumab), MAH: Alexion Europe SAS, Rapporteur: Arantxa Sancho-Lopez, Co-Rapporteur: Pierre Demolis, "Update of sections 4.1 and 5.1 of the SmPC with an extension of the indication in patients with Paroxysmal nocturnal haemoglobinuria (PNH) regardless of their history of transfusion. The PL has been updated accordingly. In addition, some minor corrections are proposed in Section 5.1 of the SmPC and in the PL." Request for Supplementary Information adopted on 24.07.2014.
The Committee discussed the issues identified in this application, mainly concerning the wording of the indication as LDH values were not considered a sufficient parameter to define the patient population.
The Committee adopted a 2nd Request for Supplementary Information with a specific timetable.

Tracleer (EMEA/H/C/000401/II/0066), (bosentan), MAH: Actelion Registration Ltd., Rapporteur: Pierre Demolis, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Arnaud Batz, "Extension of Indication to include treatment of symptomatic pulmonary arterial hypertension in paediatric patients aged from 3 months to 18 years. The SmPC has been updated in order to include the data generated in studies conducted according to the agreed Paediatric Investigationa Plan for bosentan (EMEA-000425-PIP02-10-M04). As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC have been updated. The Package Leaflet has been updated accordingly. In addition, taking into account the new data in the paediatric population, an updated version of the RMP (version 5) has been provided."
Request for Supplementary Information adopted on 24.07.2014.
The Committee discussed the issues identified in this application and noticed that the applicant had withdrawn the indication in children below 1 year.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive Opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The CHMP noted the letter of recommendations dated 17.11.2014
The summary of opinion was circulated for information.

Travatan (EMEA/H/C/000390/II/0046), (travoprost), MAH: Alcon Laboratories (UK) Ltd, Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Dolores Montero Corominas, "Extension of the therapeutic indication for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the package leaflet are updated."
Request for Supplementary Information adopted on 25.09.2014.
The Committee discussed the issues identified in this application, which mainly related to the efficacy in the paediatric population in comparison with other authorised products.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive Opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.

4.2. Update on on-going type II variation; extension of indications

No items

5. Ancillary medicinal substances in medical devices

5.1. Ancillary medicinal substances in medical devices - Opinions/ List of outstanding issues / List of Questions

No items

6. Re-examination procedure (new applications) under Article 9(2) of Regulation no 726/2004

No items

7. Re-examination procedure (Type II variations) under Article Article 16 of Commission Regulation (EC) No 1234/2008 and 9(2) of Regulation (EC) No 726/2004

No items

8. Withdrawal of full new application

Egranli (EMEA/H/C/002637), (balugrastim), Applicant: Teva Pharma B.V., (treatment of neutropenia)
New active substance (Article 8(3) of Directive No 2001/83/EC). Positive Opinion adopted on 25 September 2014.
Letter from the applicant dated 6 November 2014 informing of a decision to withdraw the Marketing
The Committee noted the letter from the applicant dated 06.11.2014 informing of a decision to withdraw the Marketing Authorisation Application.

9. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

10. Pre-submission issues

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.
(H0003882) (Alirocumab), (Alirocumab is indicated, as adjunct therapy to diet, for long-term treatment of adult patients with primary hypercholesterolaemia (non-familial and heterozygous familial) or mixed dyslipidaemia to reduce low-density lipoprotein cholesterol (LDL-C).
Combination therapy with a statin:
Alirocumab is indicated in combination with a statin (HMG-CoA reductase inhibitor), with or without other lipid modifying therapy (LMT), in patients not appropriately controlled with a statin alone.
Monotherapy:
Alirocumab is indicated as monotherapy, or as add-on to other non-statin LMT, in patients who cannot tolerate statins),
The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

(H0004062) (Sacubitril/Valsartan), (indicated for the treatment of heart failure (NYHA class II-IV) to reduce the rate of cardiovascular death and heart failure hospitalization. TRADENAME was also shown to reduce all-cause mortality),
The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

(H0004004), Orphan (Sebelipase Alfa), Applicant: Synageva BioPharma Ltd, (indicated for long-term enzyme replacement therapy (ERT) for patients with Lysosomal Acid Lipase Deficiency (LAL D).).
The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

11. Post-authorisation issues

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

ellaOne (EMEA/H/C/001027/II/0021), (ulipristal acetate), MAH: Laboratoire HRA Pharma, SA, Rapporteur: Pieter de Graeff, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst
"Change in the classification for supply of ellaOne from "medicinal product subject to medical prescription" to "medicinal product not subject to medical prescription". An update of the Product information in line with a non-prescription setting was performed. Updates of SmPC sections 4.2, 4.4 and 5.1 were also performed based on Repeated use study (HRA2914-554) and on the STEella study in postmenarcheal girls and adult women (HRA 2914-515). Additionally, the contraindication "pregnancy" was removed based on available non-clinical and clinical data. Updates to Annex II, labelling and package leaflet have been made accordingly. Furthermore, changes were made to the PI to bring it in line with the current Agency/QRD template. In addition, editorial changes have been made in the Product Information."
Request for Supplementary Information adopted on 23.01.2014, 21.11.2013, 25.04.2013.
Request for 1 year of data exclusivity for a change in classification (Article 74(a) of Directive 2001/83/EC)
See also 1.3 Post-authorisation procedure oral explanation
An Oral explanation was held on Tuesday 18 November 2014 at 11.00. The MAH presented the clinical data supporting the claim to change the product to non-prescription status. Furthermore data from their pregnancy and safety databases after 5 years of marketing of the product was presented. After the Oral Explanation the Committee discussed the available data and whether a switch to OTC status could be acceptable. The members also discussed a possible restriction for adolescents. It was highlighted that different national regulations exist which need to be considered.
The Committee adopted a positive opinion by majority (21 positive out of 29 votes) recommending the granting of the variation together with the CHMP assessment report and translation timetable.
The CHMP agreed to the 1-year of data exclusivity by majority (21 positive out of 29 votes).
The legal status was agreed as medicinal product not subject to medical prescription.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
Two divergent positions (John Joseph Borg), (Ivana Mikacic, Agnes Gyurasics, Harald Enzmann, Piotr Fiedor, Romaldas Maciulaitis, Jan Mueller-Berghaus, Daniela Melchiorri) were appended to the opinion.
The Committee noted the letter of recommendation dated 19.11.2014.
The CHMP agreed to the wording of the EMA press release.

Ferriprox (EMEA/H/C/000236/II/0089/G), (deferiprone), MAH: Apotex Europe BV, Rapporteur: Pierre Demolis, PRAC Rapporteur: Isabelle Robine, , "Update of section 4.5 of the SmPC regarding combination of deferiprone with other iron chelators further to request of the PRAC in the assessment of the PSUR (PSUV/083). Update of section 5.1 of the SmPC and the RMP with the results of Study LA37-111 conducted to evaluate the effect of deferiprone on cardiac QT and QTC interval duration. The

Package leaflet is updated accordingly. The MAH also takes the opportunity to align the product information with QRD template (version 9) and to make minor editorial corrections. The package leaflet is also updated to add the local representatives in Croatia." Request for Supplementary Information adopted on 24.07.2014.
The CHMP noted the letters from patient and several patients' organisations on use of deferiprone administered in combination with other iron chelators.
The Committee discussed the proposal to include a warning on the combination of Ferriprox with other chelator therapies in the SmPC of Ferriprox instead of a contraindication and agreed to include a warning. The CHMP agreed on the need for consistency for all concerned products.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Brintellix (EMEA/H/C/002717/II/0004), (vortioxetine), MAH: H. Lundbeck A/S, Rapporteur: Bart Van der Schueren "Update of section 5.1 of the SmPC with information on the effect of vortioxetine on cognitive dysfunction in Major Depressive Disorder."
The Committee adopted a Request for Supplementary Information with a specific timetable.

Herceptin (EMEA/H/C/000278/II/0084/G), (trastuzumab), MAH: Roche Registration Ltd, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.2 and 4.8 of the SmPC with information on switching between intravenous (IV) and subcutaneous (SC) formulations further to safety data from study MO22982. The Package Leaflet is updated accordingly. Update of section 4.2 with a statement regarding switching between Herceptin and biosimilars. In addition, the MAH took the opportunity make corrections to the SmPC and Package leaflet."
The Committee adopted a Request for Supplementary Information with a specific timetable.

Revlimid (EMEA/H/C/000717/II/0076), Orphan, (lenalidomide), MAH: Celgene Europe Limited, Rapporteur: Pierre Demolis "Update of section 4.4 of the SmPC with a new warning regarding an increased risk of mortality with the use of Revlimid in patients with chronic lymphocytic leukemia (CLL). The package leaflet is updated accordingly."
Request for Supplementary Information adopted on 26.06.2014.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Vectibix (EMEA/H/C/000741/R/0064), (panitumumab), MAH: Amgen Europe B.V., Rapporteur: Robert James Hemmings, PRAC Rapporteur: Julie Williams,
Renewal procedure. The CHMP noted that all conditions to marketing authorisations have been fulfilled. The CHMP adopted an opinion by consensus recommending switching from a conditional to full marketing authorisation.

Hexacima (EMEA/H/C/002702/ PSUV 011)
Hexyon (EMEA/H/C/002796/ PSUV 013)
Hexaxim (EMEA/H/W/002495/ PSUV 019)
(Diphtheria Toxoid,Filamentous Haemagglutinin,Hepatitis B Surface Antigen,Pertussis Toxoid,Tetanus Toxoid,Haemophilus Influenzae Type B Polysaccharide,Polyribosylribitol Phosphate Conjugated To Tetanus Protein,Type 1 (Mahoney),Type 2 (Mef-1),Type 3 (Saukett)), MAH: Sanofi Pasteur MSD SNC, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Daniel Brasseur, (treatment of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b.)
The CHMP noted the outcome of the PRAC discussion.
The Committee agreed to consult the VWP and adopted a list of questions to this group with a specific timetable.

12. Referral procedures

12.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

Procoralan (EMEA/H/C/000597)
Corlentor (EMEA/H/C/000598)
Procedure number: EMEA/H/A20/1404/C/000597-598/0031-0032
(ivabradine hydrochloride), MAH: Les Laboratoires Servier, Rapporteur: Pieter de Graeff, Co-Rapporteur: Janne Komi,
Article 20 procedure triggered by the EC to assess how the results of the SIGNIFY study, which showed a statistically significant increase in a composite endpoint of cardiovascular death and non-fatal MI in a pre-defined subgroup of symptomatic angina patients, impact on the benefit-risk balance of Corlentor and Procoralan.
The Committee discussed the benefit / risk issues, which were related to dose and the occurrence of bradycardia and how the risk minimization measures in SmPC should be presented. The members discussed the study results. The PRAC recommendation, which was about the 1st line indication in angina pectoris, was discussed. The other proposed indication was 2nd line indication to other alternatives (e.g resistant to beta-blockers). The DHPC wording was discussed.
The CHMP having considered the PRAC recommendation, adopted an opinion by majority (29 out of 31) recommending the variation of the marketing authorisations for Procoralan and Corlentor.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The divergent position (Dimitrios Kouvelas, Pierre Demolis) was appended to the opinion.
The CHMP noted the DHPC and EMA public health communication.

12.2. Requests for CHMP Opinion under Article 5(3) and 57 (1)p of Regulation (EC) No 726/2004

Medicinal products under development for the treatment of Ebola (EMEA/H/A-5(3)/1410)
The CHMP discussed the data available for the investigational medicinal products for treatment of Ebola. The Committee agreed to an interim report The CHMP interim assessment report was adopted via written procedure after the Plenary on Friday 25.11.2014.The members noted that the concerned pharmaceutical companies will be contacted to identify commercially confidential information prior to publication.
The report will be published on the EMA website after deletion of commercially confidential information, as per usual procedure. In addition, the Committee adopted a 2nd List of Questions to the companies involved in the review. A rolling assessment will be undertaken when new data emerge.
The CHMP interim report will be updated once new relevant information becomes available.

12.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

No items

12.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

Seasonique film coated tablets (EMEA/H/A-29(4)/1392)
(levonogestrel 150 µg and ethinylestradiol 30 µg / 10 µg), MAH: Teva Pharma B.V (NL), Rapporteur: Joseph Emmerich, Co-Rapporteur: Martina Weise, , RMS: FR, CMS: AT, BE, DE, IT, PL, RO, SI ,SK, Procedure number: FR/H/0516/001/DC
Article 29(4) triggered due to disagreement with regard to the demonstration of contraceptive effectiveness and treatment compliance. Opinion adopted on 26.06.2014.
The Committee reviewed the updates of the assessment report.The Committee addressed the request from the European Commission for clarification in relation to the CHMP Opinion adopted for Seasonique film coated tablets at its June 2014 meeting.
The CHMP adopted a revised opinion by majority (22 out of 31 votes) together with the assessment report.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The divergent position (Agnes Gyurasics, Alar Irs, Bruno Sepodes, Daniela Melchiorri, Harald Enzmann, Jan Mueller-Berghaus, Jens Heisterberg, Outi Mäki-Ikola, Ondrej Slanar) was appended to the revised opinion.

12.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

Nasonex (EMEA/H/A-30/1374) (mometasone), nasal spray suspension, MAH: Merck Sharp & Dohme, Rapporteur: Kristina Dunder, Co-Rapporteur: David Lyons,
Nasonex was included in the list of products for SmPC harmonisation, drawn up by the CMDh, in accordance with Article 30(2) of Directive 2001/83/EC. List of Questions adopted on 19.09.2013. List of Outstanding Issues adopted on 23.10.2014, 25.09.2014, 20.02.2014.
The CHMP adopted an opinion by consensus recommending the variation to the terms of the Marketing Authorisation together with the assessment report.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The public health communication document was circulated for information.

12.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

GVK Biosciences (EMEA/H/A-31/1408)
Rapporteur: Harald Enzmann, Co-Rapporteur: Christian Schneider,
Article 31 procedure triggered by the European Commission concerning GVK Biosciences Private Limited (GVK Bio), Swarna Jayanthi commercial complex, Ameerpet, Hyderabad 500 038, India
The Committee adopted a List of Questions to all concerned MAHs with a specific timetable:
List of outstanding issues to MAHs: November 2014 CHMP
Submission of responses: 01.12.2014
Re-start of the procedure: 23.12.2014
Co-Rapporteurs assessment reports circulated to CHMP: 12.01.2015
Rapporteur overall assessment report circulated to CHMP: 14.01.2015
Comments from CHMP: 16.01.2015
List of outstanding issues or CHMP opinion: January 2015 CHMP

Post-meeting note: the updated timetable, regarding the change in submission of responses date, was adopted via written procedure on 1st December 2014: Submission of responses: 04.12.2014

Gadolinium containing contrast agents, Gd-Cas (EMEA/H/A-31/1097),
Rapporteur: Rafe Suvarna, Co-Rapporteur: Pieter de Graeff,
FUM related to the updated 3rd annual cumulative safety reviews on nephrogenic systemic fibrosis (NSF) with regards to Omniscan: GE HealthCare
The Committee adopted the Assessment report for Post-Authorisation Commitments.

12.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

12.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

12.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003)

No items

12.10. Procedure under Article 29 Regulation (EC) 1901/2006

No items

12.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

No items

13. Pharmacovigilance issues

Summary of recommendations and advice of PRAC meeting held on 3-6 November 2014: **For information**	The Committee noted the report. The members noted the Summary of recommendations and advices of the PRAC meeting.
List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for November 2014: **For adoption**	The EURD list was adopted.
Early Notification System:	See individual items

November 2014 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Public: **for information**	
Signal detection PRAC recommendations on signals adopted at the 3-6 November 2014 meeting: **For adoption** **Tecfidera (EMEA/H/C/002601)** (Dimethyl Fumarate), MAH: Biogen Idec Ltd, Rapporteur: Martina Weise, Co-Rapporteur: Robert James Hemmings, (treatment of multiple sclerosis), Known active substance (Article 8(3) of Directive No 2001/83/EC) **Signal of Progressive multifocal leukoencephalopathy (PML)** • DHPC: **For review and adoption**	The Committee discussed the risk (causal association of progressive multifocal leukoencephalopathy with dimethyl fumarate) related to the product. The fatal case of progressive multifocal leukoencephalopathy, which occurred in October 2014, was discussed in PRAC November meeting. The CHMP noted the PRAC recommendation on signals for Tecfidera by consensus. The Icelandic and Norwegian Members were in agreement with the CHMP recommendation. Furthermore the CHMP agreed to the wording of the DHPC.

14. Inspections

14.1. GMP inspections

Request for GMP inspections: **For adoption**	*Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections.*

14.2. GCP inspections

Request for GCP inspections: **For adoption**	*Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections.*

14.3. Pharmacovigilance inspections

Request for Pharmacovigilance inspections: **For adoption**	*Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections.*

14.4. GLP inspections

Request for GLP inspections: **For adoption**	*Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections.*

15. Innovation Task Force

15.1. Minutes of Innovation Task Force: For information

15.2. Briefing meetings (Innovation Task Force)

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information.

15.3. Eligibility to EMA scientific services

No items

15.4. Requests for CHMP Opinion under Article 57 (1)P of Regulation (EC) No 726/2004

Request from EC for EMA scientific Opinion under Art. 57 (1)P of Regulation (EC) No 726/ • Appointment of CHMP coordinator: **For discussion**	The CHMP adopted a specific timetable and the coordinators.

15.5. Nanomedicine activities

No items

16. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 3-6 November 2014. Table of conclusions: **For information**	The CHMP noted the report.
Scientific advice letters:	*Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.*

17. Satellite Groups

17.1. Coordination Group for Mutual Recognition and Decentralised Procedures

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 17-19 November 2014: **For information**	The CHMP noted the report.
Letter from CMDh to CHMP (PKWP) regarding potential risk of longer half-life of acitretin: **For information**	The CHMP noted the letter.
Letter to CHMP (PKWP) regarding tacrolimus containing products – evaluation of Bioequivalence: **For information**	The CHMP noted the letter.
PKWP's response to the CMDh request on the Applicability of BCS-based biowaivers (EMA/CMDh/613179/2014): **For adoption**	The CHMP adopted the PKWP's response.

18. Other Committees

18.1. Committee for Orphan Medicinal Products (COMP)

Press release of the COMP meeting held on 12-23 November 2014: **For information**	To be sent in the Post-mail.

18.2. Committee for Herbal Medicinal Products (HMPC)

Not applicable this month.

18.3. Paediatric Committee (PDCO)

PIPs reaching D30 November 2014 PDCO: **For information**	To be sent in the Post-mail.
Report from the PDCO meeting held on 12-14 November 2014: **For information**	The CHMP noted the report.

18.4. Committee for Advanced Therapies (CAT)

Table of Decisions of CAT meeting held on 13-14 November 2014: **For information**	The CHMP noted the table of decisions.

19. Invented name issues

Not applicable this month.

20. Any other business

Initiative on registries: tools to improve the quality, consistency and utility of data and information from patient registries: **For discussion**	The members were informed about the establishment of a Cross-Agency Taskforce to develop a strategy paper and to start discussions. A pilot phase of the EU Collaborative Network was proposed on 2-4 patient registries. Comments on the proposal should be sent to Xavier Kurz (Xavier.kurz@ema.europa.eu).
Presentations given at the CHMP, CAT, COMP joint Presidency meeting, 29 – 30 October 2014 in Rome: **For information**	The CHMP noted the presentations given at the joint Italian Presidency meeting in Rome.
Participation of the centralised procedure in the IGDRP-Information sharing pilot	The centralised procedure will participate in the "IGDRP-Information sharing pilot". Under this pilot all assessment reports (from D120 to D210) will be shared with participating non-EEA agencies, for selected applications of generic medicinal products. The anticipated start date is January 2015, first assessment reports are expected to be shared by the agency from May 2015. The CHMP endorsed the participation.
Questions and answers on propylene glycol in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (EMA/CHMP/704195/2013): **For adoption for 3-month public consultation** Draft background report (EMA/CHMP/334655/2013): **For information**	The CHMP adopted the Q&A for 3-months public consultation.
Questions and answers on cyclodextrins in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' (EMA/CHMP/495747/2013): **For adoption for 3-month public consultation** Draft background report (EMA/CHMP/333892/2013): **For information**	The CHMP adopted the Q&A for 3-months public consultation.
CHMP Safety Working Party's response to the CHMP query regarding the contra-indication for pregnancy is justifiable on the basis of non-clinical data of apremilast (EMA/CHMP/SWP/680234/2014): **For adoption,**	The CHMP adopted the SWP response

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (Doc Ref: EMEA/CHMP/BMWP/42832/2005 Rev1): **For adoption,**	Postponed
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms - EMA/CHMP/669973/2014: **For adoption**	The CHMP adopted the guideline.
Update to Committees about changes to the MAA process: **For information**	The CHMP noted the update See also topic below
Draft Guidance with applicants on responses to questions received from EMA Scientific Committees during the evaluation within the centralised procedure: **For comments by 5 December 2014**	Comments on proposed guidance should be sent by 5 December 2014.
Adjustment of timetable for procedures in phase outcome in December 2014/January 2015	The members noted that procedural deadlines concerning the CHMP, which fall into the period of 26.12.14 – 02.01.2015, will be postponed to 05.01.2015.
Benefit/Risk workshop update	The members were updated on a benefit risk workshop to be held at EMA

21. List of participants:

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 17-20 November 2014 meeting.

CHMP Chair	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restrictions applies Product/substance
Tomas Salmonson	Sweden	Full involvement	

CHMP Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restrictions applies Product/substance
Andrea Laslop	Austria	Full involvement	
Daniel Brasseur	Belgium	Full involvement	
Mila Vlaskovska	Bulgaria	Full involvement	
Ivana Mikacic	Croatia	Full involvement	
Panayiotis Triantafyllis	Cyprus	Full involvement	
Ondřej Slanař	Czech Republic	No participation in final deliberations and voting	(EMEA/H/C/003971), (sevelamer)
			(EMEA/H/C/003899), (aripiprazole)
			(H0003882) (Alirocumab)
			Brintellix (EMEA/H/C/002717/II/0004), (vortioxetine)
			Invega (EMEA/H/C/000746/II/0043), (paliperidone)
			(EMEA/H/C/003926), (aripiprazole)
			(EMEA/H/C/003803), (aripiprazole)
			(EMEA/H/C/004008), (aripiprazole)
			(EMEA/H/C/003823), (lamivudine / raltegravir)
			(EMEA/H/C/003904), (atazanavir / cobicistat)
			(EMEA/H/C/003837), (dasabuvir),
			(EMEA/H/C/003839), (ombitasvir / paritaprevir / ritonavir)
			(EMEA/H/C/002784), (sufentanil)
			Travatan (EMEA/H/C/000390/II/0046),

CHMP Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restrictions applies Product / substance
			(travoprost)
			(EMEA/H/C/003785), (oritavancin)
			Cosentyx (EMEA/H/C/003729), (secukinumab)
			Otezla (EMEA/H/C/003746), (apremilast)
			(EMEA/H/C/003737), (voriconazole)
Jens Heisterberg	Denmark	No participation in final deliberations and voting	Brintellix (EMEA/H/C/002717/II/0004), (vortioxetine)
			(EMEA/H/C/003899), (aripiprazole)
			(EMEA/H/C/003926), (aripiprazole)
			(EMEA/H/C/003803), (aripiprazole)
			(EMEA/H/C/004008), (aripiprazole)
			Invega (EMEA/H/C/000746/II/0043), (paliperidone)
Alar Irs	Estonia	Full involvement	
Outi Mäki-Ikola	Finland	No participation in final deliberations and voting	Cosentyx (EMEA/H/C/003729), (secukinumab)
			Otezla (EMEA/H/C/003746), (apremilast)
			(H0003882) (Alirocumab)
			Procoralan (EMEA/H/C/000597) Corlentor (EMEA/H/C/000598)
			Rienso (EMEA/H/C/002215/II/0008), (ferumoxytol)
			(EMEA/H/C/003971), (sevelamer)
			Vectibix (EMEA/H/C/000741/R/0064), (panitumumab)
Pierre Demolis	France	Full involvement	
Harald Enzmann	Germany	Full involvement	
Dimitrios Kouvelas	Greece	Full involvement	
Agnes Gyurasics	Hungary	Full involvement	
Kolbeinn Gudmundsson	Iceland	Full involvement	
David Lyons	Ireland	Full involvement	

CHMP Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restrictions applies Product/substance
Daniela Melchiorri	Italy	Full involvement	
Juris Pokrotnieks	Latvia	No participation in final deliberations and voting	Rienso (EMEA/H/C/002215/II/0008), (ferumoxytol)
			Ferriprox (EMEA/H/C/000236/II/0089/G), (deferiprone)
			Adenuric (EMEA/H/C/000777/II/0037), (febuxostat)
Romaldas Mačiulaitis	Lithuania	Full involvement	
Jacqueline Genoux-Hames	Luxembourg	Full involvement	
John Joseph Borg	Malta	Full involvement	
Pieter de Graeff	Netherlands	Full involvement	
Karsten Bruins Slot	Norway	Full involvement	
Piotr Fiedor	Poland	Full involvement	
Bruno Sepodes	Portugal	Full involvement	
Nela Vilceanu	Romania	Full involvement	
Stanislav Primožič	Slovenia	Full involvement Via TC	
Jan Mazag	Slovakia	Full involvement	
Concepcion Prieto Yerro	Spain	Full involvement	
Kristina Dunder	Sweden	Full involvement	
Greg Markey	United Kingdom	Full involvement	
Robert James Hemmings	Co-Opted	Full involvement	
Sol Ruiz	Co-Opted	Full involvement	
Jean-Louis Robert	Co-Opted	Full involvement	
Jan Mueller-Berghaus	Co-Opted	Full involvement	

CHMP Alternate	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restrictions applies Product/substance
Milena Stain	Austria	Full involvement	
Bart Van der Schueren	Belgium	Full involvement	

CHMP Alternate	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restrictions applies Product/substance
Radka Montoniová	Czech Republic	Full involvement	
Janne Komi	Finland	Full involvement	
Joseph Emmerich	France	No participation in final deliberations and voting	(EMEA/H/C/004006), (clopidogrel)
			(EMEA/H/C/002629), (edoxaban)
			(EMEA/H/C/002814), (vorapaxar)
Martina Weise	Germany	Full involvement	
George Aislaitner	Greece	Full involvement	
Patrick Salmon	Ireland	Full involvement	
Natalja Karpova	Latvia	Full involvement	
Johann Lodewijk Hillege	Netherlands	Full involvement	
Ingunn Hagen Westgaard	Norway	Full involvement	
Dinah Duarte	Portugal	Full involvement	
Arantxa Sancho-Lopez	Spain	Full involvement	
Filip Josephson	Sweden	Full involvement	
Rafe Suvarna	United Kingdom	Full involvement	

European Commission	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance
	European Commission	Full involvement	

CHMP Expert	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
* Experts were only evaluated against the product they have been invited to talk about.			
Theis Moeslund Jensen	Denmark	Full involvement	
Valerie Lescrainier	Belgium	Full involvement	
Sabine Mayrhofer	Germany	Full involvement	
Eirini Apostolidou	Greece	Full involvement	

CHMP Expert	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
Patricia Silva	Portugal	Full involvement	
Ana Alonso Gutierrez	Spain	Full involvement	
John Johnston	United Kingdom	Full involvement	
Emmanouil Zouridakis	United Kingdom	Full involvement	
Jonathan Sisson	United Kingdom	Full involvement	
Jason Wakelin-Smith	United Kingdom	Full involvement	
Julia Saperia	United Kingdom	Full involvement	
Sabine Lenton	United Kingdom	Full involvement	
Jens van Wijngaarden	Netherlands	Full involvement	
Anna Maria Gerdina Pasmooij	Netherlands	Full involvement	
Elisabeth Johanne Rook	Netherlands	Full involvement	
Eva Blahutova	Slovakia	Full involvement	
Jana Schweigertova	Slovakia	Full involvement	
Marion Perrin	France	Full involvement	
Nathalie Morgensztejn	France	Full involvement	
Marc Martin	France	Full involvement	
Tô Quynh Gandolphe	France	No participation in final deliberations as regards to (EMEA/H/C/003823), (lamivudine / raltegravir) Nasonex (EMEA/H/A-30/1374) (mometasone), nasal spray suspension (EMEA/H/C/002814), (vorapaxar)	

CHMP Expert by phone	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
* Experts were only evaluated against the product they have been invited to talk about.			
Antonio Gomez-Outes	Spain	Full involvement	
Teresa Dannert Alsasua	Spain	Full involvement	
Jan Willem van der Laan	Netherlands	Full involvement	

CHMP Expert by phone	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
Franz Xaver Kleber	Germany	No participation in final deliberations: (EMEA/H/C/002814), (vorapaxar)	
Clemens Mittmann	Germany	Full involvement	
Joachim Ludwig	Germany	Full involvement	
Elmer Schabel	Germany	Full involvement	
Godehard Krollmann	Germany	Full involvement	
Geraldine O'Dea	Ireland	Full involvement	
Olivier Le Blaye	France	Full involvement	
Janneke van Leeuwen	Netherlands	Full involvement	
Kommerie Hendrik	Netherlands	Full involvement	
Lies Van Vlijmen	Netherlands	Full involvement	
Karen Goetz	Germany	Full involvement	
Volker Oeppling	Germany	Full involvement	
Drew Meek	WHO	Full involvement	
Bertil Jonsson	Sweden	Full involvement	
Frank Holtkamp	Netherlands	Full involvement	

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 1)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 2 and 3) or referral procedures (section 12) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

New applications *(section 2)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 2.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 2.2 (**Day 180 List of outstanding issues**) and 2.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 2.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 2.5, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 3)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 4)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 3. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 5)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 6)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 7)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 8)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 9)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 10)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 11)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 12)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 13)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 14)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 15)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 16)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 17)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 18)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.